Form 4: Director Vacirca Acquires Caris Life Sciences Stock

Caris Life Sciences Director Jeff L. Vacirca acquired 2,492 shares of common stock in lieu of cash compensation for board retainer fees.

Summary

• Director Jeff L. Vacirca acquired 2,492 shares of Caris Life Sciences, Inc. common stock.
• The transaction occurred on February 26, 2026, at a price of $20.06 per share.
• These shares were issued in lieu of cash compensation for his 2025 board retainer fees.
• Following this transaction, Mr. Vacirca beneficially owns 18,621 shares of common stock.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, indicating management's confidence and alignment with shareholder interests through equity compensation, though it's a routine transaction.

Positives

• Director Vacirca's decision to accept shares instead of cash for board fees demonstrates alignment of interests with shareholders.
• An increase in insider ownership can signal confidence in the company's future prospects.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance.

Industry Context

StockSavvy.ai notes that equity compensation for board members is a common practice in the life sciences industry, aligning director incentives with long-term shareholder value, particularly for growth-oriented companies like Caris Life Sciences.

Comparison to Industry Standards

• Accepting equity in lieu of cash compensation is a standard practice among directors in high-growth biotech and life sciences companies, similar to practices seen at companies like Guardant Health (GH) or Exact Sciences (EXAS), where director compensation often includes a significant equity component to foster long-term commitment and share price alignment.
• The specific valuation method, using a volume-weighted average price (VWAP) over a period, is a transparent and commonly accepted method for determining share issuance prices in such compensation arrangements, comparable to methods used by other publicly traded firms for equity grants.

Stakeholder Impact

• Shareholders: The acquisition of shares by a director in lieu of cash compensation generally signals confidence in the company's future, potentially viewed positively by shareholders as it aligns director incentives with shareholder value.
• Employees: No direct impact on employees is indicated.
• Customers: No direct impact on customers is indicated.
• Suppliers: No direct impact on suppliers is indicated.
• Creditors: No direct impact on creditors is indicated.

Key Dates

Recommendation

This Form 4 filing details a routine equity compensation event for a director, rather than a discretionary open market purchase or sale. While it shows alignment of interests, it does not provide new fundamental information about the company's operational performance or strategic direction that would warrant a change in investment recommendation. Therefore, a "hold" recommendation is appropriate, maintaining current positions based on existing company fundamentals.

Keywords

Caris Life Sciences, CAI, Form 4, Insider Trading, Stock Acquisition, Director Compensation, Equity Compensation, Beneficial Ownership